SG Americas Securities LLC Makes New $511,000 Investment in Zai Lab Limited (NASDAQ:ZLAB)

SG Americas Securities LLC acquired a new position in Zai Lab Limited (NASDAQ:ZLAB - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 19,502 shares of the company's stock, valued at approximately $511,000.

A number of other institutional investors and hedge funds have also modified their holdings of ZLAB. Janus Henderson Group PLC raised its stake in shares of Zai Lab by 34.2% in the 3rd quarter. Janus Henderson Group PLC now owns 8,760,074 shares of the company's stock valued at $211,488,000 after acquiring an additional 2,232,507 shares in the last quarter. Wellington Management Group LLP lifted its position in shares of Zai Lab by 18.4% during the 3rd quarter. Wellington Management Group LLP now owns 8,436,606 shares of the company's stock worth $203,660,000 after buying an additional 1,312,115 shares during the period. Bamco Inc. NY grew its holdings in shares of Zai Lab by 6.4% in the 3rd quarter. Bamco Inc. NY now owns 1,906,520 shares of the company's stock worth $46,023,000 after purchasing an additional 113,869 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. increased its holdings in shares of Zai Lab by 26.2% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 604,153 shares of the company's stock worth $14,584,000 after buying an additional 125,532 shares in the last quarter. Finally, Hennion & Walsh Asset Management Inc. boosted its stake in Zai Lab by 28.9% in the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 183,317 shares of the company's stock worth $4,801,000 after purchasing an additional 41,128 shares in the last quarter. Hedge funds and other institutional investors own 41.65% of the company's stock.

Insider Buying and Selling

In other Zai Lab news, insider Rafael Amado sold 7,583 shares of the stock in a transaction dated Tuesday, December 31st. The stock was sold at an average price of $26.28, for a total transaction of $199,281.24. Following the completion of the sale, the insider now directly owns 33,834 shares in the company, valued at approximately $889,157.52. This trade represents a 18.31 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 13.88% of the stock is owned by corporate insiders.

Zai Lab Stock Performance

Shares of NASDAQ ZLAB traded up $0.16 during mid-day trading on Wednesday, reaching $26.93. The company had a trading volume of 803,957 shares, compared to its average volume of 644,885. The business's 50-day simple moving average is $26.62 and its 200 day simple moving average is $24.38. Zai Lab Limited has a one year low of $13.48 and a one year high of $36.60. The firm has a market cap of $2.95 billion, a price-to-earnings ratio of -9.72 and a beta of 1.02.

Wall Street Analyst Weigh In

ZLAB has been the topic of a number of recent research reports. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Zai Lab in a research note on Friday, October 25th. JPMorgan Chase & Co. increased their price objective on shares of Zai Lab from $38.00 to $44.00 and gave the stock an "overweight" rating in a research report on Monday, October 21st.

Zai Lab Profile

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.